Sunshine Biopharma Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 105/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sunshine Biopharma Inc's Score
Industry at a Glance
Industry Ranking
105 / 158
Overall Ranking
308 / 4562
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
6.000
Target Price
+313.79%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Sunshine Biopharma Inc Highlights
StrengthsRisks
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 702.52% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 34.87M.
Overvalued
The company’s latest PE is 0.25, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 128.14K shares, decreasing 68.34% quarter-over-quarter.
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Ticker SymbolSBFM
CompanySunshine Biopharma Inc
CEOSlilaty (Steve N)
Websitehttps://www.sunshinebiopharma.com/
FAQs
What is the current price of Sunshine Biopharma Inc (SBFM)?
The current price of Sunshine Biopharma Inc (SBFM) is 1.310.
What is the symbol of Sunshine Biopharma Inc?
The ticker symbol of Sunshine Biopharma Inc is SBFM.
What is the 52-week high of Sunshine Biopharma Inc?
The 52-week high of Sunshine Biopharma Inc is 3.900.
What is the 52-week low of Sunshine Biopharma Inc?
The 52-week low of Sunshine Biopharma Inc is 1.169.
What is the market capitalization of Sunshine Biopharma Inc?
The market capitalization of Sunshine Biopharma Inc is 5.97M.
What is the net income of Sunshine Biopharma Inc?
The net income of Sunshine Biopharma Inc is -5.13M.
Is Sunshine Biopharma Inc (SBFM) currently rated as Buy, Hold, or Sell?
According to analysts, Sunshine Biopharma Inc (SBFM) has an overall rating of Buy, with a price target of 6.000.
What is the Earnings Per Share (EPS TTM) of Sunshine Biopharma Inc (SBFM)?
The Earnings Per Share (EPS TTM) of Sunshine Biopharma Inc (SBFM) is 5.318.